Consensus Update for Systemic Treatment of Atopic Dermatitis
- Author:
Ji Hyun LEE
1
;
Jung Eun KIM
;
Gyeong-Hun PARK
;
Jung Min BAE
;
Ji Yeon BYUN
;
Min Kyung SHIN
;
Tae Young HAN
;
Seung Phil HONG
;
Yong Hyun JANG
;
Hye One KIM
;
Chan Ho NA
;
Bark-Lynn LEW
;
JiYoung AHN
;
Chang Ook PARK
;
Young-Joon SEO
;
Yang Won LEE
;
Sang Wook SON
;
Eung Ho CHOI
;
Young Lip PARK
;
Joo Young ROH
Author Information
- Publication Type:Original Article
- From:Annals of Dermatology 2021;33(6):497-514
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:In 2015, the Korean Atopic Dermatitis Association (KADA) working group published consensus guidelines for treating atopic dermatitis (AD).
Objective:We aimed to provide updated consensus recommendations for systemic treatment of AD in South Korea based on recent evidence and experience.
Methods:We compiled a database of references from relevant systematic reviews and guidelines on the systemic management of AD. Evidence for each statement was graded and classified based on thestrength of the recommendation. Forty-two council members from the KADA participated in three rounds of voting to establish a consensus on expert recommendations.
Results:We do not recommend long-term treatment with systemic steroids forpatients with moderate-to-severe AD due to the risk of adverse effects. We recommend treatment with cyclosporine or dupilumab and selective treatment with methotrexate or azathioprine for patients with moderate-to-severe AD. We suggest treatment with antihistamines as an option for alleviating clinical symptoms of AD. We recommend selective treatment with narrowband ultraviolet B for patients with chronic moderate-to-severe AD. We do not recommend treatment with oral antibiotics for patients with moderate-to-severe AD but who have no signs of infection. We did not reach a consensus on recommendations for treatment with allergen-specific immunotherapy, probiotics, evening primrose oil, orvitamin D for patients with moderate-to-severe AD. We also recommend educational interventions and counselling for patients with AD and caregivers to improve the treatment success rate.
Conclusion:We look forward to implementing a new and updated consensus of systemic therapy in controlling patients with moderate-to-severe AD.
